PT-141 vs Melanotan II: What Melanocortin Research Shows

PT-141 vs Melanotan II is really a comparison of one molecule and its metabolite. Melanotan II (MT2) is a cyclic synthetic analogue of alpha-melanocyte-stimulating hormone that activates several melanocortin receptors, including the MC1R receptor that drives skin pigmentation. PT-141, known generically as bremelanotide, is MT2 with its C-terminal amide replaced by a carboxylic acid, and its clinical development focused on the central MC4R pathway rather than tanning. In the UK both are sold strictly as research chemicals with no MHRA marketing authorisation.

The two peptides are often lumped together online, but the literature treats them quite differently. Bremelanotide went through two phase 3 trials and was licensed by the US FDA in 2019, while Melanotan II never completed a full clinical programme and is the subject of repeated public warnings from the MHRA. This article walks through the chemistry, the receptor pharmacology, the trials, the safety literature and the UK legal position, so that researchers can see what the evidence supports and what it does not.

Where PT-141 and Melanotan II come from

Both compounds trace back to work at the University of Arizona in the 1980s, where Victor Hruby, Mac Hadley and colleagues were designing stable analogues of alpha-MSH, the natural 13-amino-acid hormone that stimulates melanocytes. Their first product, Melanotan I (afamelanotide), is a linear analogue that later became a licensed medicine in Europe for erythropoietic protoporphyria under the brand name Scenesse. Melanotan II followed as a shorter, cyclic lactam-bridged version with much greater potency and a longer duration of action.

PT-141 emerged from the same programme when researchers noticed that MT2 was partly converted in the body into a des-amide metabolite. That metabolite, bremelanotide, retained the effects on sexual arousal seen in early MT2 studies but was developed as a separate drug candidate by Palatin Technologies. The single-atom difference between an amide and a hydroxyl group at the C-terminus is the whole of the structural distinction between the two peptides.

Melanocortin receptors: what each peptide binds

The melanocortin system has five receptors. MC1R on melanocytes controls eumelanin production and therefore pigmentation. MC2R is the ACTH receptor in the adrenal cortex. MC3R and MC4R are expressed mainly in the brain, where MC4R in particular regulates energy balance, autonomic tone and sexual function. MC5R is found in exocrine glands.

Melanotan II is a non-selective agonist at MC1R, MC3R, MC4R and MC5R, which explains why the earliest human studies recorded tanning, nausea, flushing and spontaneous erections all at once. PT-141 also binds MC1R, MC3R and MC4R, and it does produce some pigmentation in the literature, but its clinical development and dosing were oriented around MC4R-mediated effects in the central nervous system. The practical difference researchers describe is one of emphasis and formulation rather than a clean receptor split.

What the Melanotan II research shows

The human record on MT2 is thin and old. In a 1996 pilot study published in Life Sciences, Dorr and colleagues gave escalating subcutaneous doses to three healthy men and reported dose-dependent darkening of the skin alongside nausea, facial flushing and unexpected spontaneous erections. That side-effect observation is what redirected the research towards sexual function.

Wessells and colleagues followed up with a double-blind, placebo-controlled crossover study in the Journal of Urology in 1998. Ten men with psychogenic erectile dysfunction received MT2 or placebo; eight of the ten had clinically apparent erections after MT2 compared with none after placebo, with nausea again the most common adverse event. A larger 2000 follow-up in Urology from the same group reported similar findings in men with both psychogenic and organic erectile dysfunction. After that the MT2 programme stopped, and the compound never entered late-phase trials.

The more recent MT2 literature is largely case reports rather than trials. Dermatology journals have documented eruptive and changing naevi, and several papers describe melanoma diagnosed in people who had been using unlicensed tanning injections; causation is not established, but the association is taken seriously by regulators because MT2 drives the same MC1R pathway involved in melanocyte proliferation. Other single-case reports include priapism, rhabdomyolysis, renal infarction and posterior reversible encephalopathy syndrome. This is the evidence base behind the MHRA's position.

What the PT-141 (bremelanotide) trials show

PT-141 has a very different paper trail. Early studies in the 2000s tested an intranasal formulation in men with erectile dysfunction and in women, and the results were mixed: there were positive signals on arousal, but a consistent, dose-related rise in blood pressure led the FDA to halt the nasal programme in 2008. The compound was reformulated as a subcutaneous injection with a lower peak concentration, and development refocused on premenopausal women with hypoactive sexual desire disorder (HSDD).

The pivotal evidence comes from the RECONNECT programme, two identical randomised, double-blind, placebo-controlled phase 3 trials reported by Kingsberg and colleagues in Obstetrics & Gynecology in 2019. Across the two studies 1,267 premenopausal women with HSDD were randomised to bremelanotide 1.75mg or placebo, self-administered on demand, for 24 weeks. Bremelanotide improved the Female Sexual Function Index desire domain by 0.35 points more than placebo and reduced the distress score (FSDS-DAO item 13) by 0.33 points more than placebo, both statistically significant but modest in absolute size.

Adverse events in RECONNECT were dominated by nausea, which affected roughly four in ten women on active treatment, along with flushing, headache and injection-site reactions. A small, transient increase in blood pressure and a fall in heart rate were seen after each dose, and focal hyperpigmentation was reported in a minority of participants, particularly with frequent use in women with darker skin. Serious adverse events occurred in 1.1% of the bremelanotide group and 0.5% of placebo. A 52-week open-label extension, published by Simon and colleagues in the same journal, reported no new safety signals.

On the strength of these trials the FDA licensed bremelanotide as Vyleesi in June 2019 for premenopausal women with acquired, generalised HSDD. The product has never been submitted for or granted an MHRA marketing authorisation, so in the UK PT-141 remains a research compound. A subsequent independent re-analysis published in the Journal of Sex & Marital Therapy questioned how clinically meaningful the effect sizes were, which is worth knowing when reading enthusiastic summaries online.

Key differences researchers should note

When the two compounds are placed side by side, five points come up repeatedly in the literature.

1. Evidence depth. PT-141 has more than 1,200 phase 3 participants and a year of open-label follow-up behind it. Melanotan II has a handful of pilot studies from the 1990s totalling fewer than 50 participants, plus case reports.
2. Pigmentation. MT2 was designed as a tanning agent and its MC1R activity is central to its profile. PT-141 produces pigmentation only as a side effect, reported in a minority of trial participants.
3. Cardiovascular signal. Both peptides raise blood pressure transiently. For PT-141 this was quantified in trials and led to the abandonment of the nasal route; for MT2 it is described mainly in case reports.
4. Melanoma concern. The naevus and melanoma case reports in the dermatology literature are specific to MT2 tanning use. No comparable signal has been reported for PT-141, though the licensed product still carries a hyperpigmentation warning.
5. Regulatory standing. PT-141 is a licensed medicine in the US under a different name. MT2 is licensed nowhere and is the subject of explicit MHRA warnings. Neither is licensed in the UK.

PT-141 and Melanotan II: UK legal status

Neither PT-141 nor Melanotan II is a controlled substance under the Misuse of Drugs Act 1971, and both can lawfully be bought, sold and possessed in the UK as research chemicals. What is not lawful is supplying either peptide for human medicinal use, or marketing it with claims about tanning, sexual function or any other effect on the body, without a marketing authorisation under the Human Medicines Regulations 2012. Neither compound has one.

Melanotan II deserves a specific note. Because the MHRA has publicly warned against its use and has actively shut down websites selling it to consumers, any supplier presenting MT2 as a tanning product is operating outside the law. Reputable UK vendors supply it only as a research reagent, describe it in the terms used by the literature, and make no claims about what it will do in a person.

What to check before buying PT-141 or MT2 in the UK

Both peptides are inexpensive to synthesise, and both are widely sold, which means quality varies enormously. The precautions are the same as for any research peptide, with one extra: because MT2 and PT-141 differ by a single terminal group, mass spectrometry identity confirmation matters more than usual, since a mislabelled batch would look identical on a purity chromatogram.

• Ask for a batch-specific certificate of analysis showing HPLC purity and mass-spectrometry identity, with a target purity above 99%. Calibre pens are tested by Janoshik Analytical and COAs are published on the site's COA page.
• Confirm the stated milligram figure is peptide content, not gross weight.
• Prefer a pre-filled, precision-made pen if the laboratory workflow benefits from consistent, ready-to-use volumes rather than reconstituting powder.
• Check that the supplier is UK-based, identifiable and contactable, and that the listing makes no medicinal or cosmetic claims.
• Store both peptides refrigerated and protected from light; cyclic melanocortin analogues are reasonably stable but still degrade with heat and repeated freeze-thaw cycles.

Summary

PT-141 and Melanotan II are chemically almost the same peptide, but the research separates them cleanly. PT-141 has a completed phase 3 programme, a US licence and a well-characterised safety profile dominated by nausea and transient blood-pressure changes. Melanotan II has a few 1990s pilot studies, a growing file of case reports and formal MHRA warnings. For UK laboratories both are legal to buy as research chemicals, neither is a medicine here, and the sensible questions are the usual ones: who tested it, what did the COA show, and is the supplier making claims it should not.